CORE: Cholesterol Altered Lipid Nanoparticles for Splenic Expression of mRNA Payloads
Advanced Healthcare Materials · 2026-05 · 15 (19)
DOI: 10.1002/adhm.202505862 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 28.03.2026. Verfasst von Eshan A Narasipura und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina At Chapel Hill, Chapel Hill, N…. Hauptthemen laut MEDLINE: Spleen, RNA, Messenger, Cholesterol, Nanoparticles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI Center Core Support, North Carolina Biotech Center Institutional Support, NIBIB NIH HHS.
Abstract (Originalsprache)
A central challenge within the field of nanomedicine is synthesizing and formulating vectors capable of extrahepatic delivery. mRNA lipid nanoparticles (LNPs) are no exception as most lipid‐based formulations, when administered systemically, facilitate delivery and expression of mRNA to the liver. To address this delivery challenge, we developed a new class of LNPs—termed C h O lesterol alte RE d lipid nanoparticles ( CORE LNPs)—designed to shift mRNA expression away from the liver and toward the spleen, a central organ for systemic immune activation. To do so, we interfaced material synthesis with computational characterization to develop a series of novel cholesterol analogs which were incorporated alongside formulation components used for mRNA delivery. These were then optimized through design of experiment to generate 78 discrete formulations and were assessed for their physical properties, cellular uptake, and endosomal escape capabilities in vitro. Importantly, in vivo studies demonstrated that CORE LNPs were well‐tolerated and achieved highly selective mRNA expression in the spleen following intravenous administration. These results suggest that interfacing synthesis with computational characterization of novel cholesterol derivatives may modulate both nanoparticle behavior and organ‐level targeting, offering a promising strategy for developing spleen‐specific mRNA therapies for vaccination and immune modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina At Chapel Hill, Chapel Hill, North Carolina, USA.
- Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
ORCID-Profile: Owen S Fenton
Förderung
- NCI Center Core Support
- North Carolina Biotech Center Institutional Support
- NIBIB NIH HHS
- NINDS NIH HHS
- NIH National Institute of Biomedical Imaging and Bioengineering award
- NIH HHS
- NIGMS NIH HHS
- NICHD NIH HHS
Zitieren
APA
Narasipura, E. A., Fung, V., VanKeulen-Miller, R., Tiwade, P. B., & Fenton, O. S. (2026). CORE: Cholesterol Altered Lipid Nanoparticles for Splenic Expression of mRNA Payloads. Advanced Healthcare Materials, 15(19). https://doi.org/10.1002/adhm.202505862
Vancouver
Narasipura EA, Fung V, VanKeulen-Miller R, Tiwade PB, Fenton OS. CORE: Cholesterol Altered Lipid Nanoparticles for Splenic Expression of mRNA Payloads. Advanced Healthcare Materials. 2026;15(19). doi:10.1002/adhm.202505862
BibTeX
@article{Narasipura2026,
author = {Narasipura, Eshan A and Fung, Vincent and VanKeulen-Miller, Rachel and Tiwade, Palas B and Fenton, Owen S},
title = {CORE: Cholesterol Altered Lipid Nanoparticles for Splenic Expression of mRNA Payloads},
journal = {Advanced Healthcare Materials},
year = {2026},
volume = {15},
number = {19},
doi = {10.1002/adhm.202505862}
}
EUVIMED